OBJECTIVES: Diffusion-weighted imaging (DWI) allows characterization of masses on the basis of their cellular density. We hypothesized that ocular melanoma has a marked diffusion restriction as seen in other malignant tumors. Furthermore, we aimed to assess whether DWI is useful to differentiate ocular melanoma from retinal detachment. MATERIALS AND METHODS: The institutional review board approved the prospective study on 44 patients investigated with ocular magnetic resonance imaging including DWI during a 9-month period. A region-of-interest analysis of diffusion-weighted images with b values of 0 and 1000 s/mm was performed to calculate the apparent diffusion coefficient (ADC) of the ocular melanoma and the retinal detachment. Three patients were excluded because DWI was nondiagnostic owing to severe artifacts; in 1 patient, the melanoma was too small for ADC calculation. Therefore, 40 patients were included in the final analysis. Ocular melanomas and detachments were compared with respect to their ADC values. The image quality of DWI was qualitatively scored by 2 readers in consensus on a 3-point scale from 1 (minor artifacts) to 3 (major artifacts). RESULTS: Ocular melanomas showed a marked diffusion restriction, and the mean (SD) ADC was 891 (172) × 10 mm/s. Twenty-nine patients (66%) had retinal detachment. The mean ADC of the ocular melanoma differed significantly (P < 0.001) from the mean ADC of the retinal detachment (1986 [375] × 10 mm/s). The image quality of DWI was rated 1 in 38 patients, 2 in 3 patients, and 3 in 3 patients. CONCLUSIONS: Ocular melanoma shows a marked diffusion restriction with an ADC of less than 1000 mm/s, which is in concordance with other malignant tumor entities. Diffusion-weighted imaging helps differentiating ocular tumors from retinal detachment and should therefore be included in the ocular magnetic resonance imaging protocol if an ocular mass is suspected.
OBJECTIVES: Diffusion-weighted imaging (DWI) allows characterization of masses on the basis of their cellular density. We hypothesized that ocular melanoma has a marked diffusion restriction as seen in other malignant tumors. Furthermore, we aimed to assess whether DWI is useful to differentiate ocular melanoma from retinal detachment. MATERIALS AND METHODS: The institutional review board approved the prospective study on 44 patients investigated with ocular magnetic resonance imaging including DWI during a 9-month period. A region-of-interest analysis of diffusion-weighted images with b values of 0 and 1000 s/mm was performed to calculate the apparent diffusion coefficient (ADC) of the ocular melanoma and the retinal detachment. Three patients were excluded because DWI was nondiagnostic owing to severe artifacts; in 1 patient, the melanoma was too small for ADC calculation. Therefore, 40 patients were included in the final analysis. Ocular melanomas and detachments were compared with respect to their ADC values. The image quality of DWI was qualitatively scored by 2 readers in consensus on a 3-point scale from 1 (minor artifacts) to 3 (major artifacts). RESULTS:Ocular melanomas showed a marked diffusion restriction, and the mean (SD) ADC was 891 (172) × 10 mm/s. Twenty-nine patients (66%) had retinal detachment. The mean ADC of the ocular melanoma differed significantly (P < 0.001) from the mean ADC of the retinal detachment (1986 [375] × 10 mm/s). The image quality of DWI was rated 1 in 38 patients, 2 in 3 patients, and 3 in 3 patients. CONCLUSIONS:Ocular melanoma shows a marked diffusion restriction with an ADC of less than 1000 mm/s, which is in concordance with other malignant tumor entities. Diffusion-weighted imaging helps differentiating ocular tumors from retinal detachment and should therefore be included in the ocular magnetic resonance imaging protocol if an ocular mass is suspected.
Authors: Mitchell Kamrava; Ali R Sepahdari; Kevin Leu; Pin-Chieh Wang; Kristofer Roberts; D Jeffrey Demanes; Tara McCannel; Benjamin M Ellingson Journal: Neuroradiology Date: 2015-05-29 Impact factor: 2.804
Authors: Pietro Valerio Foti; Renato Farina; Maria Coronella; Stefano Palmucci; Angelo Montana; Alessandra Sigona; Michele Reibaldi; Antonio Longo; Andrea Russo; Teresio Avitabile; Rosario Caltabiano; Lidia Puzzo; Marco Ragusa; Cesare Mariotti; Pietro Milone; Giovanni Carlo Ettorre Journal: Radiol Med Date: 2015-01-13 Impact factor: 3.469
Authors: Andrea Russo; Cesare Mariotti; Antonio Longo; Pietro Valerio Foti; Teresio Avitabile; Maurizio Giacinto Uva; Livio Marco Franco; Vincenza Bonfiglio; Pietro Milone; Giovanni Carlo Ettorre; Marco Ragusa; Michele Purrello; Rosario Caltabiano; Lidia Puzzo; Michele Reibaldi Journal: Radiol Med Date: 2015-02-04 Impact factor: 3.469
Authors: Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz Journal: Cancers (Basel) Date: 2022-06-27 Impact factor: 6.575
Authors: Pietro Valerio Foti; Antonio Longo; Michele Reibaldi; Andrea Russo; Giuseppe Privitera; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Renato Farina; Stefano Palmucci; Andrea Musumeci; Rosario Caltabiano; Marco Ragusa; Cesare Mariotti; Teresio Avitabile; Pietro Milone; Giovanni Carlo Ettorre Journal: Radiol Med Date: 2016-10-17 Impact factor: 3.469
Authors: Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile Journal: Insights Imaging Date: 2021-06-03